72 results about "Agalactosis" patented technology

The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

The invention relates to a feed additive and a production method thereof. The feed additive comprises beta-carotene, VE, potassium chloride, magnesium sulfate, ferrous glycinate, yeast selenium, folicacid, vitamin B1, sodium sulfate and the like, and is a high-efficiency nutritious functional compound premix which is designed specially aiming at the problems troubling the pig industry, such as reduction of reproductive capacity and milking capacity of sows, heat stress and the like. The invention can effectively relieve the heat stress caused by climate and environment, prevent the occurrenceof sow agalactosis, improve the reproductive performance, prolong the breeding time and improve the survival rate of embryos, thereby increasing the litter size of sows, increasing the weight of newborn piglets, improving the survival rate and increasing the weight of weaning litter.

An deactivated multi-bacterium vaccine for preventing the mastitis of milk cow is composed of Staphylococcus aureus, agalactic streptococcus, milk-stopping streptococcus, breast streptococcus, colibacillus and aluminum hydroxide gel. Its preparing process includes such steps as choosing the pathogenic bacterial strain of said mastitis, preparing seed liquid and reproduction liquid, purity checking, deactivating, preparing vaccine, and discriminating.

The invention relates to a traditional Chinese medicine which is suitable for parturient women with hypogalactia during lactation, a preparation method and a detection method thereof. According to the invention, Chinese angelica and Astragalus mongholicus are used as the principal drugs, Bupleurum Chinense and Ligusticum wallichii are used as the ministerial drugs, and Vaccaria segetalis, MedullaTetrapanacis and Fructus Liquidambaris are used as the adjuvant drugs. The traditional Chinese medicine provided by the invention has functions of tonifying qi and nourishing blood, relieving qi stagnancy in liver, and dredging collateral for promoting lactation, and can be used to treat symptoms such as postpartum hypogalactia or lactation deficiency; or clear and thin breast milk; or pale complexion, mental fatigue and deprivation; or hypochondriac and distending pains as well as depressed mood.

The invention discloses a method for constructing an anti-mammitis transgenic mouse model and a special vector for the method. An anti-mammitis-related protein composition comprises lysostaphin and peptidoglycan endolysin B30; the peptidoglycan endolysin B30 derives from a Streptococcus agalactiae phage B30, and an amino acid sequence of the peptidoglycan endolysin B30 is sequence 2 in a sequence table; and an amino acid sequence of the lysostaphin is sequence 3 in the sequence table. The experiment proves that a transgenic plasmid for mammary gland-specific expression of the lysostaphin and the peptidoglycan endolysin B30 is constructed by using a mammary gland-specific expression vector; and the anti-mammitis transgenic mouse model is constructed by a microinjection method, a transgenic mouse with an anti-bovine mastitis gene is obtained, and a technical model is provided for further producing anti-mammitis transgenic calves.

The invention aims at providing a traditional Chinese medicine for adjusting the insufficient lactation and the agalactosis of sow, wherein the traditional Chinese medicine is good in treatment effects, free from side effects, and selected from pure natural good-quality traditional Chinese medicine materials. The traditional Chinese medicine is characterized by comprising the following raw materials, i.e. phaseolus calcaratus, the seed of cowherb, tetrapanax papyriferus, sweetgum fruit, eucommia ulmoides, herba lycopi, leonurus, astragalus mongholicus, Chinese angelica, codonopsis pilosula, herba epimedii, semen cuscutae, the fruit of Chinese wolfberry, glossy privet fruit, dandelion, soybean, sesame and crucian. A preparation method of the traditional Chinese medicine comprises the following steps of: removing the entrails of the crucian, putting into a marmite with the raw materials, adding water of which the quantity is three times that of the mixture, boiling by big fire, stewing by soft fire for 30-40min, and removing slag of filter liquor; feeding the liquid medicine to the sow after the liquid medicine is cooled three times per day and 500g per time, and stopping feeding the liquid medicine after the traditional Chinese medicine becomes effective. The liquid medicine is fed to the sow after the method of the traditional Chinese medicine is adopted, so that the sow can quickly recover the bodily function, the fecundity and the premonition can be improved, the appetite can be enhanced, the digestion can be promoted, the traditional Chinese medicine has the function of promoting lactation, and the quality and the quantity of the milk of the sow can be improved, so that the sow health can be guaranteed, and the sow has strong disease resistance.

The invention discloses a preparation method and application of a tilapia source streptococcus agalactiae recombinant GroEL protein vaccine. The recombinant GroEL protein vaccine is prepared by tilapia source streptococcus agalactiae recombinant GroEL protein. An amino acid sequence of the tilapia source streptococcus agalactiae recombinant GroEL protein is as shown in SEQ ID NO.2. In the invention, tilapia source streptococcus agalactiae is taken as a research object, a GroEL gene is obtained from a tilapia source streptococcus agalactiae genome by cloning, the cloned GroEL gene is connected with a pET28a(+) carrier to construct an expression vector, and the vector is subjected to prokaryotic expression and purification in E.coli BL21(DE3) to obtain the recombinant GroEL protein vaccine with strong specificity and an immune protective efficacy of 68.61+/-7.39 percent, so that a foundation is laid for immune prevention and treatment of a tilapia streptococcus agalactiae disease.

The invention provides a lactating sow feed for improving the production performance of sows and piglets. The technical characteristics include: mixing a variety of monomer vitamins, a carrier, traceelements with various amino acids, an enzyme preparation, calcium dihydrogen phosphate and the like into a premix; crushing first-class corn, soybean meal and the like with a wide pulverizer; mixing the crushed first-class corn, soybean meal with the premix, puffed soybean flour, wheat bran, oil and the like; employing double-layer conditioning to ensure soil certain ripening degree and make particles; utilizing a cooler for cooling, and performing dehydration to obtain a finished product. The feed provided by the invention can effectively avoid the problems of constipation, lacrimal spots andsurface crusting in sows, shorten the sow parturition, reduce the occurrence of postpartum triad syndromes (mastitis, hysteritis, and agalactosis), and improve the production performance of lactatingsows. The feed provides sufficient nutrition to sows during lactation, improves the average weaning weight of piglets, the weaning litter weight of piglets, the average daily gain of piglets and theaverage daily lactation yield of sows, shortens the weaning-oestrus interval of lactating sows, can achieve rapid estrus mating in 3-5 days and large litter size.

The invention discloses recombinant lactococcus lactis based on the fbsA gene of Streptococcus agalactiae. The recombinant lactococcus lactis comprises the fbsA gene of Streptococcus agalactiae or segments of the fbsA gene, the fbsA gene or the segments of the fbsA gene preferably has (or have) a sequence shown in SEQ ID No. 1, the deposit number of the recombinant lactococcus lactis is CCTCC M 2020140, and expression of recombinant FbsA protein with a theoretical molecular weight of 34.6 kDa can be induced under the culture condition that niusin exists. The invention also provides a vaccine for the Streptococcus agalactiae disease of Oreochromis sp., and the vaccine is prepared from the recombinant lactococcus lactis, and is capable of producing protective antibodies in Oreochromis sp. after Oreochromis sp. is fed with the vaccine in an immune mode of oral gavage, so that Oreochromis sp. is assisted to resist infection of Streptococcus agalactiae effectively.

The invention discloses an application of plectasin in inhibiting streptococcus agalactiae. The plectasin is found to be good at inhibiting the streptococcus agalactiae through bacteriostasis experiments; the plectasin is further prepared into corresponding agentia, such as plectasin gel and plectasin emulsion, the agentia achieve good curative effects for mastitis, wherein the antibacterial anti-inflammatory effect of the gel is better, the action time lasts longer, the moisturizing effect is better, action sites can be effectively isolated from making contact with air, and a wound is prevented from infection and inflammation. The plectasin can be used for preparing bacteriostat of the streptococcus agalactiae and further used for curing the mastitis, and especially for the mastitis caused by the streptococcus agalactiae which is difficult to cure at present, and a good curative effect is achieved.

The invention discloses a rapid separation and identification kit for streptococcus agalactiae. In the kit, the following reagents are included: sheep defibering blood plate, 3% H2O2, staphylococcus aureus strains, a specific PCR (polymerase chain reaction) solution, and positive control DNA (deoxyribonucleic acid). The rapid separation and identification kit for streptococcus agalactiae provided by the invention has the following beneficial effects that bacterial morphological observation, catalase test, CAMP (cyclic adenylic acid) reaction and PCR detection are used together, so that identification procedures can be simplified, the specificity is strong, and the sensitivity is increased by more than 15%; and moreover, the identification cost is low, the time consumption is short (only needing 3 days), and streptococcus agalactiae strains can be obtained by separation and accurately identified. The kit can be used for separation and identification for the samples of the milk samples of human or dairy cows, cervical mucus, vaginal swabs and the like.

The invention provides a LAMP (Loop-Mediated Isothermal Amplification) primer group, a micro-fluidic chip and a kit for detecting reproductive tract pathogenic microorganisms, and belongs to the technical field of reproductive tract infection detection. The LAMP primer group comprises a streptococcus agalactiae detection primer group, an enterococcus faecalis primer group, a gardnerella vaginosisprimer group, a Candida albicans primer group and a Chlamydia trachomatis primer group. The above LAMP primer group is fixed on the micro-fluidic chip. The LAMP primer group, the micro-fluidic chip and the kit can quickly, sensitively and accurately detect streptococcus agalactiae, enterococcus faecalis, gardnerella vaginosis, Candida albicans and Chlamydia trachomatis by high repeatability.

The invention discloses a method for constructing a high-yield glutathione recombinant strain and application, and belongs to the field of bioengineering. The method for constructing the high-yield glutathione recombinant strain is characterized in that corynebacterium glutamicum for synthesizing a large amount of glutamic acid is used as an original strain, and a gene gshF from streptococcus agalactiae or genes gshA and gshB from escherichia coli are introduced to endow glutathione with the synthesis capability; further genome is subjected to deletion of genes aceD, mcbR and sdaA; a truncatedgene serA, a gene pgk, genes cysE and cysK derived from the escherichia coli and a gene cysE derived from arabidopsis thaliana are expressed at the same time, and a cysteine pathway is strengthened;and as the corynebacterium glutamicum can synthesize a large amount of the glutamic acid and the cysteine pathway is strengthened, the glutathione can be highly produced only by adding glycine in a fermentation process of obtained engineering bacteria.

The invention relates to a culture-independent semiquantitative detection kit of tilapia streptococcus agalactiae, which consists of a reagent A, a reagent B, a reagent C, a reagent D, a reagent E, a product specification and a test result record card. The kit can be used for directly detecting whether blood of tilapia carries the streptococcus agalactiae without pure culture by a method provided by the invention, and semiquantitatively detect the quantity of the streptococcus agalactiae in the blood.

The invention relates to recombinant Lactococcus lactis comprising a fusion gene of a sip gene and a pgk gene of Streptococcus agalactiae, and the fusion gene is introduced into the Lactococcus lactisby a plasmid vector. The fusion gene has a DNA sequence as shown in SEQ No. 1. The plasmid vector is a pNZ8148 vector. The lactococcus lactis is Lactococcus. lactis NZ9000. The invention further provides a tilapia mossambica streptococcus agalactiae disease vaccine. The tilapia mossambica streptococcus agalactiae disease vaccine comprises the recombinant lactococcus lactis. Wherein the recombinant lactococcus lactis is the recombinant lactococcus lactis induced by nisin. The vaccine is the vaccine administrated by oral administration and intragastric administration. The tilapia mossambica streptococcus agalactiae disease vaccine comprises the recombinant lactococcus lactis with the concentration of 2*10 <10> cfu mL <-1>, and the administration dosage is 200 [mu]L.

The invention relates to a loop-mediated isothermal amplification primer for detecting streptococcus agalactiae of tilapias. The primer is designed according to a conserved sequence of a surface immunogenic gene of the streptococcus agalactiae of the tilapias and comprises sip-F3, sip-B3, sip-FIP and sip-BIP respectively shown by SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4. A loop-mediated isothermal amplification method for detecting the streptococcus agalactiae of the tilapias can be established according to the designed primer. In the method, cross reactions with several common pathogenic bacteria of aquatic animals and several common pathogenic bacteria of streptococcus cannot happen. The detection method provided by the invention does not need expensive instruments, and is short in time, simple in operation and high in sensitivity.

The invention discloses a preparation method and application of a micro-capsule coated egg yolk antibody IgY resistant to main pathogenic bacteria of dairy cow mastitis. A compound mycoprotein antigen is prepared by selecting streptococcus agalactiae, streptococcus dysgalactiae, staphylococcus aureus and escherichia coli and is mixed with an equal quantity of freund's adjuvant to prepare a multivalence antigen immune complex, laying hens are immune by adopting repeatedly alternative immune procedures and a muscular and subcutaneous multipoint injection means, a specific yolk immunoglobulin IgY resistant to the main pathogenic bacteria of dairy cow mastitis, namely DP-BM-IgY, is separated and purified from collected egg yolk, then homogeneous emulsification is conducted on the specific yolk immunoglobulin and a sodium alginate water solution and an emulsifying agent soya bean salad oil containing span-80, the emulsified solution is dropwise added into an encystation solution prepared from CaCl2 and chitosan for coating and curing, and the coated micro-capsules can effectively protect the activity of the DP-BM-IgY and have enteric solubility. The preparation method utilizes a micro-capsule technology and selects the chitosan and sodium alginate as coating materials (natural polysaccharides), and the egg yolk antibody is internally taken and free of any toxic or side effect.

The invention belongs to the technical field of aquaculture preparations, and discloses a feed additive for preventing streptococcus agalactiae, being prepared from the following components by mass percent: 10-15 percent of coptis chinensis, 7-15 percent of honeysuckle, 7-15 percent of isatis root, 10-20 percent of Houttuynia cordata, 20-40 percent of black soya bean and 0-20 percent of dendrobe. The additive is added into tilapia feed, has a highest immune protective rate of 95.21 percent for tilapia, and has practical and wide application values; the survival rate of the tilapia is 93.67 percent.

The invention discloses a health medicined diet for the treatment of postparturient agalactia, and the health medicined diet is prepared from the following main raw materials in parts by weight: 1.5-2.5 parts of seven-hole pig trotters, 1.0-2.0 parts of crucian, 0.4-0.8 part of chickweed, 1.0-1.5 parts of luffa, 0.8-1.2 parts of astragalus membranaceus, 0.3-0.5 part of juggins mandshurica fruit nuts, 0.1-0.2 part of eguanshi, 0.2-0.5 part of artemisia anomala, 0.8-1.5 parts of angelica sinensis, 0.3-0.5 part of pleione bulbocodioides, and 0.2-0.4 part of chastetree. The health medicined diet has the functions of conducing circulation and promoting circulation of human milk, eliminating stagnation to stop pain, clearing heat and dispersing blood stasis, and can be used for effectively enhancing the secretion of milk.

The invention relates to a tilapia streptococcus agalactiae vaccine and a preparation method thereof. According to bioinformatics principles, a part of polypeptide sequences of a surface anchoring protein of streptococcus agalactiae are analyzed and screened as an antigen for preparing the vaccine, in addition, a carbon nanotube carried surface protein system is constructed by using a chemical synthesis technology, and the selected polypeptide antigen is in nano combination with functionalized single-wall carbon nanotubes, so that a tilapia streptococcus agalactiae subunit vaccine is prepared.The polypeptide antigen screened by the invention is capable of remarkably increasing the antibody level of inoculated tilapia when being compared with an inactivated vaccine, and is capable of resisting attack of streptococcus agalactiae of high toxicity. In addition, the polypeptide antigen screened by the invention can be tightly and uniformly connected with surfaces of functionalization modified carbon nanotubes, and compared with independent polypeptide antigen groups, the polypeptide antigen is capable of remarkably improving the immunity of the tilapia.

The invention provides a nursing agent for balancing a gynecological micro-ecological flora structure. The nursing agent comprises water, a surfactant, a humectant, a preservative and a thickening agent, and core functional components comprise a composition of micromolecular organic acid and a composition of saccharides and saccharide derivatives. The care agent realizes an obvious sterilization effect on escherichia coli, staphylococcus aureus and streptococcus agalactiae and an obvious bacteriostasis effect on candida albicans, effectively inhibits the growth of harmful bacteria, also can promote the growth of probiotic lactobacillus in the genital tract, and really plays a role in balancing healthy micro-ecological flora.

The invention discloses a drug for preventing and treating sow agalactosis and breast distending pain and a preparation method thereof. The drug is prepared from, by mass, 120-180 parts of akebiaquinata, 70-100 parts of safflower carthamus, 190-230 parts of dandelion, 110-180 parts of snow lotus herbs, 120-200 parts of leonurus, 130-210 parts of schizonepeta, 200-250 parts of herba lycopi, 120-190 parts of herba patriniae, 200-280 parts of ricepaper pith, 100-140 parts of ginseng, 200-250 parts of astragalus membranaceus and 250-320 parts of polygonum orientale. According to the drug, the postpartum anti-infection ability of sows can be enhanced, the sow lactation yield is increased, the lactating sow feed intake can be significantly increased, the reproductive performance of the sows is improved, and the piglet growth performance is improved.

The invention discloses a functional food for treating women's mastopathy, wherein the food is prepared from deer horn cap through steps of extracting, heating to 50-115 deg C and cooling down, husking and removing tendon, carrying out biological mildew, disintegrating and breaking cell wall, obtaining powdered antler with grain size below 180 meshes, disintegrating sika deer venison and mixing homogeneously with deer horn cap powder, proportioning with wild chrysanthemum flower, honeysuckle flower and pagodatree flower. The food can be used for treating women's lactiferous gland, mastadenitis, mammary cancer and agalactosis.

The invention relates to the technical field of animal feed, and particularly discloses a feed for improving mammary gland development and postpartum agalactia of sows and a preparation method. The feed is prepared from the following raw materials in parts by weight: 65-75 parts of corn; 25-35 parts of wheat bran; 15 to 25 parts of soybean meal; 15-25 parts of rice bran; 1-5 parts of nicotinic acid; 1-5 parts of oleic acid; 1-5 parts of a lactation promoting additive; 1-5 parts of a vitamin additive; 1-5 parts of an inorganic salt additive. The preparation method comprises the following steps: L1, mixing the corn, the wheat bran, the soybean meal and the rice bran, stirring and crushing to obtain a primary crushed material; L2, uniformly mixing the primary crushed material, the nicotinic acid, the oleic acid, the vitamin additive and the inorganic salt additive to obtain a secondary mixture; and L3, adding the lactation promoting additive and purified water into the secondary mixture, uniformly stirring and mixing to obtain paste, drying the paste, and granulating in a granulator to obtain the feed composition. The feed provided by the invention can be used for feeding sows and can improve mammary gland development and postpartum agalactia of the sows.

The invention relates to recombinant lactococcus lactis based on a pgk gene comprising a pgk gene of Streptococcus agalactiae, the pgk gene is introduced into the lactococcus lactis by a plasmid vector. The pgk gene has a DNA sequence as shown in SEQ No. 1, and the plasmid vector is a pNZ8148 vector, wherein the lactococcus lactis is lactococcus lactis NZ9000. The invention also provides a tilapiamossambica streptococcus agalactiae disease vaccine which comprises the recombinant lactococcus lactis, and the recombinant lactococcus lactis is induced and cultured in the presence of nisin. The vaccine is a vaccine for oral intragastric administration. The tilapia mossambica streptococcus agalactiae disease vaccine comprises the recombinant lactococcus lactis with the concentration of 2*10 <10> cfu mL <-1>. The administration dosage of the vaccine is 200 [mu]L.